Citius Pharmaceuticals, Inc. (CTXR) Stock Price & Analysis
Citius Pharmaceuticals, Inc. (CTXR) rose 2.52% to USD 0.6 as of September 8, 2026 at 16:20 UTC, according to Nexqual real-time market data.
CTXR last closed at USD 0.6; the session ranged USD 0.58–0.62 on volume of 199,411 shares. Market capitalization is —, with a 52-week range of USD 0.47–2.19 (NCM). Source: Nexqual, September 8, 2026 at 16:20 UTC.
Key Statistics (as of September 8, 2026 at 16:20 UTC)
| Price | USD 0.6 |
|---|---|
| Change | ▲ 2.52% (up) |
| Previous Close | USD 0.6 |
| Open | USD 0.6 |
| Day Range | USD 0.58 – 0.62 |
| 52-Week Range | USD 0.47 – 2.19 |
| Volume | 199,411 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (CTXR)
Nexqual's technical model rates CTXR "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of September 8, 2026 at 16:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 50.56 (neutral) |
| vs SMA50 | Above (USD 0.6) |
| MACD | -0.01 (negative) |
From Citius Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2025-12-23)
Key Strengths & Strategy (as disclosed to the SEC)
- As the FDA considered this a new product, an Investigational New Drug Application ("IND") was filed.
- Moreover, no new safety signals were identified.    In December 2022, a Biologics License Application ("BLA") for LYMPHIR was accepted for filing with the FDA and a PDUFA goal date was set for July 28, 2023.   In July 2023, the FDA issued a complete response letter ("CRL") requiring us to incorporate enhanced product testing and additional controls agreed to with the FDA during the market application review.
- The FDA provided clear, constructive, and actionable guidance during the discussion, underscoring a pathway to support a future New Drug Application (NDA) submission for Mino-Lok.
- Citius Pharma will continue to have ongoing engagement with the FDA regarding the next steps of development.    17   Market Opportunity   The current market for OTC and topical prescription ("Rx") products for the symptomatic treatment of hemorrhoids is highly fragmented and includes approximately 20 million units of OTC and over 4 million prescriptions.
Partnerships
- SpinCo began operations in April 2022, when Citius Pharma transferred the assets related to LYMPHIR to SpinCo, including the related license agreement with Eisai Co., Ltd. ("Eisai") and the related asset purchase agreement with Dr.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATOS | Atossa Therapeutics, Inc. | USD 2.55 | ▲ 0.79% |
| TNXP | Tonix Pharmaceuticals Holding C | USD 12.88 | ▼ 3.64% |
| GNPX | Genprex, Inc. | USD 3.58 | ▲ 4.38% |
| SENS | Senseonics Holdings, Inc. | USD 9.39 | ▼ 5.15% |
| DARE | Dare Bioscience, Inc. | USD 0.71 | ▼ 0.28% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 16:20 UTC. This page is informational and not investment advice.